Microbiological clearance · women with PID
Regimens containing macrolides (azithromycin) showed no clear difference in microbiological clearance compared with regimens containing tetracycline (doxycycline); GRADE not reported.
1 finding from 1 review
RR 1.02 [0.98, 1.06]
Studies not reported
GRADE not reported
Laparoscopic evidence of resolution of PID based on physician opinion · women with PID
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Length of stay · women with PID
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Fertility outcome · women with PID
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Clinical cure according to criteria established by study authors Mild‐moderate PID · women with PID
Regimens containing quinolone showed no clear difference in clinical cure according to criteria established by study authors… compared with regimens containing cephalosporins (low certainty).
1 finding from 1 review
RR 1.05 [0.98, 1.14]
Studies not reported
Low
50% or greater reduction in seizure frequency · people with drug‐resistant focal epilepsy
Rufinamide probably leads to higher 50% or greater reduction in seizure frequency ‐ ITT analysis compared with placebo (moderate certainty).
1 finding from 1 review
Adverse effects: diplopia · people with drug‐resistant focal epilepsy
Rufinamide may leads to higher adverse effects: diplopia compared with placebo (low certainty).
1 finding from 1 review
Seizure freedom · people with drug‐resistant focal epilepsy
Rufinamide showed no clear difference in seizure freedom compared with placebo (moderate certainty).
1 finding from 1 review
Treatment withdrawal · people with drug‐resistant focal epilepsy
Rufinamide probably leads to higher treatment withdrawal compared with placebo (moderate certainty).
1 finding from 1 review
Frequency of adverse effects ‐ dizziness ( · people with drug‐resistant focal epilepsy
Rufinamide probably leads to higher adverse effects: dizziness compared with placebo (moderate certainty).
1 finding from 1 review
Adverse effect: fatigue · people with drug‐resistant focal epilepsy
Rufinamide probably leads to higher adverse effects: fatigue compared with placebo (moderate certainty).
1 finding from 1 review
Adverse effects: headache · people with drug‐resistant focal epilepsy
Rufinamide probably leads to higher adverse effects: headache compared with placebo (moderate certainty).
1 finding from 1 review
Somnolence · people with drug‐resistant focal epilepsy
Rufinamide probably leads to higher adverse effects: somnolence compared with placebo (moderate certainty).
1 finding from 1 review
Nausea · people with drug‐resistant focal epilepsy
Rufinamide probably leads to higher adverse effects: nausea compared with placebo (moderate certainty).
1 finding from 1 review
Vomiting · people with drug‐resistant focal epilepsy
Rufinamide may leads to higher adverse effects: vomiting compared with placebo (low certainty).
1 finding from 1 review
Intervention not reported
Overall BPSD (multidomain) – not assessed · dementia
The review found no eligible studies for this question.
1 finding from 1 review
Intervention not reported
Agitation · dementia
1 finding from 1 review
Intervention not reported
Depression – assessed in one study as "withdrawn behaviours" which included a lack of interest and sad mood · dementia
1 finding from 1 review
Intervention not reported
Anxiety ‐ not measured · dementia
The review found no eligible studies for this question.
1 finding from 1 review
Intervention not reported
Quality of life ‐ not measured · dementia
The review found no eligible studies for this question.
1 finding from 1 review